biostudies-literatureWang HYNational Natural Science Foundation of ChinaNatural Science Foundation of Guangdong Province973-982https://www.ebi.ac.uk/biostudies/studies/S-EPMC8524032biostudies-literatureUnknown53(4)<h4>Purpose</h4>Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice.<h4>Materials and methods</h4>TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-ligCancer research and treatmentPan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.PMC8524032816024682020A1515010313Yang XHLi YQHe YLong YKZhang XWang FDeng LTang TFeng YFWang HYfalsePan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.<h4>Purpose</h4>Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice.<h4>Materials and methods</h4>TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-lig2021-01-01T00:00:00Z2021 Oct2025-04-19T06:08:05.87Z2025-04-19T06:08:05.87ZS-EPMC85240323367784810.4143/crt.2020.798